Who
Daniel Joseph OConnell
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, Acumen Pharmaceuticals.
In numbers
- Trades disclosed
- 37
- Buys
- 0
- Sells
- 11
- Bought
- $0
- Sold
- $487K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 6 Jul 2021
- Last trade
- 22 Jan 2026
- Last filed
- 23 Jan 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 22 Jan 2026filed 23 Jan 2026 | ABOS Acumen PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $5,0662,689 at $1.88 | filing |
| 22 Jan 2026filed 23 Jan 2026 | ABOS Acumen PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $5,0552,689 at $1.88 | filing |
| 21 Jan 2026filed 23 Jan 2026 | ABOS Acumen PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $17K9,346 at $1.81 | filing |
| 21 Jan 2026filed 23 Jan 2026 | ABOS Acumen PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $17K9,346 at $1.81 | filing |
| 20 Jan 2026filed 21 Jan 2026 | ABOS Acumen PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —299,800 at $0.00 | filing |
| 20 Jan 2026filed 21 Jan 2026 | ABOS Acumen Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —450,000 at $0.00 | filing |
| 20 Jan 2026filed 21 Jan 2026 | ABOS Acumen Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —450,000 at $0.00 | filing |
| 20 Jan 2026filed 21 Jan 2026 | ABOS Acumen PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —299,800 at $0.00 | filing |
| 12 Jan 2026filed 12 Jan 2026 | ABOS Acumen PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $9,3075,388 at $1.73 | filing |
| 12 Jan 2026filed 12 Jan 2026 | ABOS Acumen PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $9,3215,388 at $1.73 | filing |
| 9 Jan 2026filed 12 Jan 2026 | ABOS Acumen PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $23K12,941 at $1.76 | filing |
| 9 Jan 2026filed 12 Jan 2026 | ABOS Acumen PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $23K12,941 at $1.76 | filing |
| 8 Jan 2026filed 12 Jan 2026 | ABOS Acumen PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $15K8,143 at $1.82 | filing |
| 8 Jan 2026filed 12 Jan 2026 | ABOS Acumen PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $15K8,143 at $1.82 | filing |
| 7 Jan 2026filed 7 Jan 2026 | ABOS Acumen PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $75K37,755 at $1.99 | filing |
| 7 Jan 2026filed 7 Jan 2026 | ABOS Acumen PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $75K37,755 at $1.99 | filing |
| 6 Jan 2026filed 7 Jan 2026 | ABOS Acumen PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $10K5,102 at $1.97 | filing |
| 6 Jan 2026filed 7 Jan 2026 | ABOS Acumen PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $10K5,102 at $1.97 | filing |
| 5 Jan 2026filed 7 Jan 2026 | ABOS Acumen PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $9,1634,649 at $1.97 | filing |
| 5 Jan 2026filed 7 Jan 2026 | ABOS Acumen PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $9,1594,649 at $1.97 | filing |
News
No headline names them, or the companies they trade most, lately.